Scientific Publications & Presentations

These scientific publications and presentations are provided for educational purposes only. They may discuss or mention DBV Technologies’ products under clinical investigation, which have not been approved for marketing by any health or regulatory authority in any country.

Key Publications

Matthew Greenhawt, M.D., Sayantani B. Sindher, M.D., Julie Wang, M.D., et al.
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
New England Journal of Medicine 2023; 388:1814-1815 | doi:10.1056/NEJMe2301157
Pongracic JA, Gagnon R, et al.
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
J Allergy Clin Immunol Pract. 2021. Nov 27;S2213-2198(21)01295-2. | doi:10.1016/j.jaip.2021.11.017
Bégin P, Bird JA, et al.
Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy
Allergy. 2021. Dec;76(12):3835-3838. | doi: 10.1111/all.15083.
Remington BC, Koppelman SJ, et al.
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Allergy. 2021. Oct;76(10):3223-3226. | doi: 10.1111/all.14973.
Brown-Whitehorn TF, de Blay F, et al.
Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy
The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):524-526. | doi: 10.1016/j.jaip.2020.08.017.
DunnGalvin A, Fleischer DM, et al.
Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies
The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):216-224.e1. | doi: 10.1016/j.jaip.2020.08.015.
Remington BC, Campbell DE, et al.
Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results
Relevance for exposure through restaurant meals. Annals of Allergy, Asthma & Immunology. 2021. Feb126(2):208-209. | doi: 10.1016/j.anai.2020.11.015.
Greenhawt M, Kim EH, et al.
Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years
The Journal of Allergy and Clinical Immunology: In Practice. 2020;S2213-2198(20)30526-2. PMID: 32502548. | doi:10.1016/j.jaip.2020.05.030.
Fleischer DM, Shreffler WG, et al.
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results
The Journal of Allergy and Clinical Immunology. 2020. | doi:10.1016/j.jaci.2020.06.028.
Fleischer DM, Chinthrajah S, et al.
An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial
Allergy & Asthma Proceedings. 2020;41:1-10. PMID: 32539908. | doi:10.2500/aap.2020.41.200047.
Fleischer DM, Spergel JM, et al.
Evaluation of daily patch application duration for epicutaneous immunotherapy for peanut allergy
Allergy & Asthma Proceedings. 2020;41:278-284. PMID: 32517847. | doi:10.2500/aap.2020.41.200045
Fleischer DM, Greenhawt M, et al.
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy
The PEPITES Randomized Clinical Trial. JAMA. 2019;321:946-955. PMID: 30794314. | doi:10.1001/jama.2019.1113.
Sampson HA, Shreffler WG, et al.
Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity
A Randomized Clinical Trial. JAMA. 2017;318:1798-1809. PMID: 29136445. | doi:10.1001/jama.2017.16591.
Get the Quarterly Newsletter from DBV Technologies Medical Affairs & Clinical Development
Subscribe

Recent Presentations

These abstracts were accepted for presentation at medical congresses and have not been subjected to full peer review.

European Academy of Allergy and Clinical Immunology (EAACI), June 9-11, 2023:

Poster Presentations:

  • Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Subjects Aged 1 Through 3 Years With and Without Concomitant Asthma in the EPITOPE Study—George Du Toit, et al. [Poster]
  • Health State Utilities in Children with Peanut Allergy and Their Caregivers: A United Kingdom Vignette Study—Marieke Schurer, et al. [Poster]
  • Characteristics and Current Management Strategies of Children Diagnosed with Peanut Allergy in the United Kingdom—Mich Erlewyn-Lajeunesse, et al. [Poster]

Eastern Allergy Conference (EAC), June 1-4, 2023:

Poster Presentations:

  • Impact of Duration of Wear on Efficacy of Epicutaneous Immunotherapy with Viaskin Peanut in Toddlers Aged 1 Through 3 Years During the Phase 3 EPITOPE Study –Todd D. Green, Katharine J. Bee, Henry T. Bahnson, et al. [Poster]

American Academy of Allergy, Asthma & Immunology (AAAAI) 2023 Annual Meeting:

Poster Presentations:

  • Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Subjects Aged 1-3 Years With and Without Concomitant Food Allergies in the EPITOPE Study –David Fleischer, M.D. [Poster 082]
  • Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Subjects Aged 1-3 Years With and Without Atopic Dermatitis in the EPITOPE Study — Amy Scurlock, M.D. [Poster 085]

American Academy of Allergy, Asthma & Immunology (AAAAI) 2022 Annual Meeting:

Poster Presentations:

  • Pooled Safety Data from Phase 3 Studies of Epicutaneous Immunotherapy for Peanut Allergy in Children Aged 4-11 Years – Rachel Robison, MD [Abstract 097]
  • Effect of Allergy Specialty Care of Healthcare Utilization Among Children with Peanut Allergy in the United States – Matthew Greenhawt, MD [Abstract 120]
  • Efficacy of Epicutaneous Immunotherapy with ViaskinTM Peanut for 4-7 Year-Old Peanut-Allergic Children in a Phase 3 Clinical Trial (PEPITES) – David Fleischer, MD [Abstract 71]
 

Canadian Society of Allergy and Clinical Immunology (CSACI) 2022 Annual Meeting:

Poster Presentations:

  • Efficacy of Epicutaneous Immunotherapy with ViaskinTM Peanut for 4-7 Year-Old Peanut-Allergic Children in a Phase 3 Clinical Trial (PEPITES) – David Fleischer, MD [Abstract 71]

American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting:

Oral Presentation:

  • EPITOPE Study Results: Phase 3, Randomized, Double-blind, Placebo-controlled Study of Epicutaneous Immunotherapy in Peanut-allergic Toddlers – Matthew Greenhawt, MD [Abstract D019]

Poster Presentation:

  • Reduction in Reaction Severity Following 12 Months of Epicutaneous Immunotherapy with Peanut Patch in Toddlers – Terri Brown-Whitehorn, MD [Abstract P183]
Scroll to Top